Related Experiment Videos
Acetazolamide affects performance on the Nagel II anomaloscope
M J Leys1, S van Slycken, T M Nork
1Department of Ophthalmology, University Hospital, State University of Ghent, Belgium.
Summary
Acetazolamide intake reduces blue-green light sensitivity in humans, affecting color vision performance. This temporary change in cone sensitivity is not clinically significant but warrants excluding patients on acetazolamide from color vision studies.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Background:
- Acetazolamide has been reported to affect human electroretinograms.
- The impact of acetazolamide on color vision, specifically using the Nagel II anomaloscope, was previously undetermined.
Purpose of the Study:
- To investigate the effects of acetazolamide on color perception.
- To determine if acetazolamide administration alters performance on the Nagel II anomaloscope.
Main Methods:
- Fifteen subjects performed luminance matches of blue-green light on a Nagel type II anomaloscope.
- Subjects ingested either 500 mg of acetazolamide or a placebo 2.5 hours prior to testing.
- Supplementary experiments included additional normal subjects and glaucoma patients before and after acetazolamide therapy.
Main Results:
- Acetazolamide ingestion led to a statistically significant shift in luminance settings, requiring more blue-green light for a match.
- This indicates reduced sensitivity to blue-green light following acetazolamide administration.
- Both normal subjects and glaucoma patients showed similar effects in supplementary tests.
Conclusions:
- Acetazolamide alters the sensitivity of cone populations, likely those containing carbonic anhydrase.
- The observed sensitivity loss is reversible and not considered clinically significant.
- Patients taking acetazolamide should be excluded from studies comparing color vision in glaucoma patients versus normal individuals.